Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 4/20 | 0.33 |
| ▸ | BCR | P11274 | 4/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16057604 | 0.88 | KMT2A (0.38) | AURKBKDRKMT2ASELPTYRO3 | |
| SCHEMBL3564725 | 0.87 | KDR (0.49) | AURKBKDRDGAT1KCNH2KMT2A | |
| SCHEMBL3574419 | 0.86 | AURKB (0.39) | AURKBKDRKMT2ASELPTYRO3 | |
| SCHEMBL12565021 | 0.85 | KMT2A (0.56) | AURKBKDRDGAT1KCNH2KMT2A | |
| SCHEMBL3579834 | 0.85 | KMT2A (0.56) | AURKBKDRDGAT1KCNH2KMT2A | |
| SCHEMBL3566624 | 0.84 | AURKB (0.38) | AURKBKDRKMT2ASELPTYRO3 | |
| SCHEMBL3566625 | 0.83 | GRM4 (0.43) | AURKBKDRKMT2ASELPTYRO3 | |
| SCHEMBL22501580 | 0.81 | SELP (0.43) | KMT2ASELPTYRO3MEN1 | |
| SCHEMBL29437412 | 0.79 | STK17B (0.43) | KMT2AABL1BCRHCRTR1 | |
| SCHEMBL4549835 | 0.79 | STK17B (0.43) | KMT2AABL1BCRHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | AURKB 1956/4885KDR 2478/4885DGAT1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.